The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

2003770 citationsJournal Article

Authors

Paul J. Hesketh · Rotterdam University of Applied Sciences

Steven M. Grunberg · Rotterdam University of Applied Sciences

Richard J. Gralla · Rotterdam University of Applied Sciences

David Warr · Rotterdam University of Applied Sciences

Fausto Roila · Rotterdam University of Applied Sciences

Ronald de Wit · Rotterdam University of Applied Sciences

Sant P. Chawla

Abstract

Compared with standard dual therapy, addition of aprepitant was generally well tolerated and provided consistently superior protection against CINV in patients receiving highly emetogenic cisplatin-based chemotherapy.

Topics & Keywords

Nausea and vomiting management Anesthesia and Pain Management Intraoperative Neuromonitoring and Anesthetic Effects

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 21, Issue 22, pp. 4112-4119

DOI: 10.1200/jco.2003.01.095

Field-Weighted Citation Impact: 29.01